Registration Document/Universal Registration Document
- 2022 Universal Registration Document (French only)
- Amendment to the 2021 Universal Registration Document (French only)
- 2021 (French)
- 2021 (English)
- 2021 (version XBRL)
- Amendment 1 to the 2020 Universal Registration Document (English)
- Amendement 1 au Document d’enregistrement universel 2020 (French)
- 2020 (English)
- 2020 (French)
- 2019 (English)
- 2019 (French)
- 2018 (English)
- 2018 (French)
- 2017 (English)
- 2017 (French)
- 2016 (English)
- 2016 (French)
- 2015 (English)
- 2015 (French)
- 2014 (English)
- 2014 (French)
- 2013 (English)
- 2013 (French)
- 2012 (French only)
- 2011 (French only)
- 2010 (French only
- 2009 (French only)
- 2008 (French only)
Archiv Hauptversammlungen
Aktien und Stimmrechtserklärung
Valneva confirms its PEA-PME eligibility
Aktienrückkaufprogramme
Liquidity Contract
Eigene Aktien
The Company holds 124,322 own ordinary shares with a par value of €0.15 each. The shares are recorded as treasury stock in the financial statements and the number and movements during the fiscal year are disclosed in the notes to the financial statements.
Directors’ Dealings
Transactions in excess of EUR 20,000 per calendar year, executed on Company’s financial instruments by persons discharging managerial responsibilities (as referred to in Article L. 621-18-2, I of the French Monetary and Financial Code), must be reported to the French Financial Markets Authority (AMF). The AMF will publish the transactions.
The publication of such transactions is available on the website of the French Financial Markets Authority (AMF).
Regulated agreements (Information pursuant to Articles L. 22-10-30 and R. 22-10-19 of the French Commercial Code)
Information on the remuneration policy
A description of Valneva’s 2021 remuneration policy is included in Section 2.6.1 of the Company’s 2020 Universal Registration Document, as filed on April 9, 2021 with the AMF under No. D.21-0286.
The 2021 Remuneration Policy was adopted by the Combined Shareholders’ Meeting of June 23, 2021, by a majority of 87.37%.
Statutory Auditors’ report on the compliance of Valneva SE with respect to the special rights attached to preferred shares
Listing Prospectus
Rights Issues
Global Offering 2022
On October 4, 2022 Valneva announced the closing of an upsized €102.9 million Global Offering.
- Press Release, September 28, 2022
- Press Release, September 30, 2022
- Press Release, October 4, 2022
- Note d’opération – Augmentation de capital réalisée le 4 octobre 2022 / Share capital increase closed on October 4, 2022 (French only)
- Amendement au Document d'enregistrement universel 2021 / Amendment to the 2021 Universal Registration Document (French only)
Global Offering 2021
On November 3, 2021 Valneva announced the closing of a Global Offering of approximately $102.0 million.
IPO 2021
On May 11, 2021 Valneva announced the closing of approximately $107.6 million Global Offering.
PIPE 2018
On September 27, 2018 Valneva announced that it has raised €50 million of gross proceeds in a private placement of its ordinary shares.
Rights Issue 2015
Valneva announces the launch of a capital increase with shareholders preferential subscription rights of approximately EUR 45 million.
Rights Issue 2013
Merger 2013
In December 2012, the Management Boards of Vivalis SA and Intercell AG announced that they have agreed the terms of a merger to create the newly-named Valneva SE, a leading European biotechnology company in vaccines and antibodies.
The shareholders of both Intercell and Vivalis have approved the merger in their respective shareholder meetings on February 27, 2013 and March 7, 2013.
The merger was completed on May 28, 2013.